Tesamorelin (TH9507): A Research Reference

Tesamorelin (TH9507): A Research Reference

Tesamorelin, also catalogued under the development code TH9507, is a synthetic analogue of growth hormone-releasing factor. It is one of the larger peptides commonly encountered in laboratory supply, and its size and structural complexity make it a useful case study in how research peptides are characterised, documented and verified. This reference summarises what defines Tesamorelin as a chemical entity and how research-grade material is analytically confirmed.

Nothing in this article addresses use of any kind. Tesamorelin is discussed here purely as a research chemical: its structure, its identifiers, its physical presentation and the analytical work that establishes identity and purity.

Chemical identity and nomenclature

Tesamorelin carries CAS registry number 218949-48-5. Its molecular formula is C221H366N72O67S, giving a molecular weight of approximately 5,135.9 g/mol. Alongside the code TH9507, literature and supply catalogues frequently describe it as a growth hormone-releasing factor analogue, and the abbreviation GRF analogue appears widely.

This multiplicity of names is typical of the field and a common source of confusion when cross-referencing suppliers or literature. A single compound may appear under a trivial name, a development code, a systematic description and one or more abbreviations. Matching CAS number and molecular formula is a far more reliable identification method than matching names.

Structural basis

Tesamorelin is a 44-amino-acid peptide. Its sequence corresponds to the naturally occurring growth hormone-releasing factor GRF(1-44), modified at the N-terminus. That modification is the defining structural feature separating Tesamorelin from unmodified GRF, and it materially changes the molecule’s stability profile in analytical conditions.

Because the peptide is long by synthetic standards, it is produced by solid-phase peptide synthesis with a correspondingly high number of coupling steps. Every additional residue introduces an opportunity for deletion sequences, incomplete couplings and side-chain protecting group artefacts. This is precisely why analytical verification carries more weight for a 44-mer than for a short peptide.

Comparison with related GRF peptides

Tesamorelin is frequently discussed alongside other GRF-related research peptides, and it is worth being precise about how they differ structurally.

• Sermorelin corresponds to GRF(1-29) — the shortest fragment retaining the core structural motif, at roughly 3,358 g/mol.
• CJC-1295 without DAC, also catalogued as Mod GRF 1-29, is a 29-residue analogue carrying four amino acid substitutions that alter its stability relative to unmodified GRF(1-29).
• Tesamorelin is the full 44-residue chain with an N-terminal modification, and is substantially larger than either.

These are distinct chemical entities with different molecular weights, different CAS numbers and different analytical signatures. They are not interchangeable in any research context. Corix Labs supplies Tesamorelin 10mg, Sermorelin 10mg and CJC-1295 without DAC 5mg as separate catalogue items for this reason.

Physical form and presentation

Research-grade Tesamorelin is supplied as a lyophilised powder, typically white to off-white, in a sealed glass vial. Lyophilisation — freeze-drying — removes water under vacuum from a frozen solution, leaving a dry cake or powder. For a peptide of this size the dried state substantially reduces the rate of hydrolytic degradation compared with a solution, which is why nearly all research peptides are distributed in this form.

The visual appearance of the cake is not a reliable purity indicator. A collapsed or shrunken cake can result from lyophilisation cycle variation rather than any problem with the material, and conversely an attractive cake tells you nothing about sequence fidelity. Only analytical data speaks to purity.

Analytical verification

Two techniques do most of the work in characterising a peptide of this class. High-performance liquid chromatography separates the target peptide from synthesis-related impurities and quantifies purity as a percentage of total peak area. Liquid chromatography-mass spectrometry confirms molecular identity by measuring mass-to-charge ratio against the theoretical value derived from the molecular formula.

For a 5,135.9 g/mol peptide, mass spectrometry typically resolves multiple charge states, and the deconvoluted mass is compared against theory. A discrepancy corresponding to a single missing residue is readily detectable, which is the principal reason LC-MS is run alongside HPLC rather than either being used alone. Research-grade material is commonly specified at greater than 98% purity by HPLC.

Documentation

A Certificate of Analysis for Tesamorelin would be expected to state the batch identifier, the analytical methods applied, the measured purity, the observed mass and the date of analysis. Batch-level documentation matters because synthesis runs vary; a purity figure from one batch says nothing definitive about another.

The batch identifier is the element that ties everything together. Without it, a Certificate of Analysis is an assertion about some material rather than a record about the material in front of you. Any documentation that omits a batch reference, or that cannot be matched to a marking on the vial itself, provides considerably weaker assurance than it appears to.

Stability considerations for large peptides

Molecular size affects how a peptide degrades. In a 44-residue chain there are forty-three peptide bonds, each in principle susceptible to hydrolysis, and a correspondingly larger number of side chains available for oxidation, deamidation and other chemical modification. The absolute number of available degradation routes is simply greater than in a short peptide.

This does not make large peptides inherently unstable, but it does mean the degradation products of a long chain are more numerous and more varied. A chromatogram of a degraded 44-mer typically shows a cluster of closely eluting species rather than one or two discrete impurity peaks, because fragments differing by a single residue have similar chromatographic behaviour.

The lyophilised state addresses the dominant route. Hydrolysis requires water, and freeze-drying removes it. What remains relevant is residual moisture content, temperature and the integrity of the vial seal — the three variables that determine how closely the material in storage resembles the material that was analysed.

Interpreting a purity specification

A specification of greater than 98% purity by HPLC is a statement about a specific analytical method applied to a specific batch, not an intrinsic property of the compound. The same material analysed on a different column, with a different gradient, or with detection at a different wavelength may return a different figure — not because the material changed but because the measurement did.

This is why methodology belongs on a Certificate of Analysis alongside the number. A purity figure quoted without the method that produced it is difficult to compare against anything.

Corix Labs publishes analytical documentation for its research materials. See third-party testing reports for further detail on how batches are verified.

All materials referenced in this article are supplied strictly for laboratory research and analytical use. They are not licensed medicines and are not sold for use in humans or animals. Nothing in this article constitutes guidance on administration, preparation for use, or any clinical, therapeutic, diagnostic or cosmetic application.